Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Non-small Cell Lung Cancer Metastatic × Bevacizumab × Clear all
NCT05407155 2026-04-23

BETTER

Fudan University

Phase NA Active not recruiting
56 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT01966003 2017-10-19

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Amgen

Phase 3 Completed
642 enrolled 17 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03240549 2017-08-07

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Beijing Hospital

Phase 2 Unknown
159 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡